CD7 is an important target in T-cell ALL and T-cell lymphoma.284–286 CD30 is usually expressed on tumor cells of HL,287 and CD33 is a favorable target for AML.288 Two CAR T-cell products, idecabtagene vicleucel and ciltacabtagene autoleucel, are the currently FDA-approved BCMA-targeting therapies. This evidence concerns the gene CD33 and acute myeloid leukemia.